Lucira Health, Inc., a medical technology company, focuses on the development and commercialization of infectious disease test kits.
Lucira Health Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$5.84|
|52 Week High||US$4.23|
|52 Week Low||US$37.99|
|1 Month Change||-23.96%|
|3 Month Change||-18.55%|
|1 Year Change||n/a|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-76.62%|
Recent News & Updates
Is Lucira Health (NASDAQ:LHDX) In A Good Position To Invest In Growth?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
|LHDX||US Medical Equipment||US Market|
Return vs Industry: Insufficient data to determine how LHDX performed against the US Medical Equipment industry.
Return vs Market: Insufficient data to determine how LHDX performed against the US Market.
Stable Share Price: LHDX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.
Volatility Over Time: LHDX's weekly volatility has decreased from 18% to 13% over the past year, but is still higher than 75% of US stocks.
About the Company
Lucira Health, Inc., a medical technology company, focuses on the development and commercialization of infectious disease test kits. It develops a testing platform that produces molecular testing services. The company offers LUCIRA COVID-19 All-In-One Test Kit, a COVID-19 test kit; and develops influenza A and B viruses test kits.
Lucira Health Fundamentals Summary
|LHDX fundamental statistics|
Is LHDX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|LHDX income statement (TTM)|
|Cost of Revenue||US$19.81m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-1.51|
|Net Profit Margin||-339.72%|
How did LHDX perform over the long term?See historical performance and comparison
Is Lucira Health undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate LHDX's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate LHDX's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: LHDX is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.
PE vs Market: LHDX is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate LHDX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: LHDX is good value based on its PB Ratio (1x) compared to the US Medical Equipment industry average (4.4x).
How is Lucira Health forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: LHDX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: LHDX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: LHDX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: LHDX's revenue (62.7% per year) is forecast to grow faster than the US market (9.9% per year).
High Growth Revenue: LHDX's revenue (62.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if LHDX's Return on Equity is forecast to be high in 3 years time
How has Lucira Health performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: LHDX is currently unprofitable.
Growing Profit Margin: LHDX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if LHDX's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare LHDX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: LHDX is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (36.1%).
Return on Equity
High ROE: LHDX has a negative Return on Equity (-27.11%), as it is currently unprofitable.
How is Lucira Health's financial position?
Financial Position Analysis
Short Term Liabilities: LHDX's short term assets ($215.9M) exceed its short term liabilities ($28.6M).
Long Term Liabilities: LHDX's short term assets ($215.9M) exceed its long term liabilities ($254.0K).
Debt to Equity History and Analysis
Debt Level: LHDX is debt free.
Reducing Debt: LHDX had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: LHDX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: LHDX has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of 80.2% each year.
What is Lucira Health current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate LHDX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate LHDX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if LHDX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if LHDX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of LHDX's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Erik Engelson (61 yo)
Mr. Erik T. Engelson has been the President and Chief Executive Officer of Lucira Health, Inc. since February 8, 2019 and has been its Director since March 2019. Mr. Engelson served as Chief Executive Offi...
CEO Compensation Analysis
Compensation vs Market: Erik's total compensation ($USD775.02K) is about average for companies of similar size in the US market ($USD1.07M).
Compensation vs Earnings: Insufficient data to compare Erik's compensation with company performance.
Experienced Management: LHDX's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.
Experienced Board: LHDX's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: LHDX only recently listed within the past 12 months.
Lucira Health, Inc.'s employee growth, exchange listings and data sources
- Name: Lucira Health, Inc.
- Ticker: LHDX
- Exchange: NasdaqGS
- Founded: 2013
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$226.001m
- Shares outstanding: 38.70m
- Website: https://www.lucirahealth.com
Number of Employees
- Lucira Health, Inc.
- 1412 62nd Street
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/20 23:27|
|End of Day Share Price||2021/10/20 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.